CO7160058A2 - Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis - Google Patents

Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis

Info

Publication number
CO7160058A2
CO7160058A2 CO14276714A CO14276714A CO7160058A2 CO 7160058 A2 CO7160058 A2 CO 7160058A2 CO 14276714 A CO14276714 A CO 14276714A CO 14276714 A CO14276714 A CO 14276714A CO 7160058 A2 CO7160058 A2 CO 7160058A2
Authority
CO
Colombia
Prior art keywords
leishmaniosis
dronedarone
associations
formulations
see annexes
Prior art date
Application number
CO14276714A
Other languages
English (en)
Spanish (es)
Inventor
Stephane Beilles
Sandra Chambonnet
Jean-Pierre Collaveri
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO7160058A2 publication Critical patent/CO7160058A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO14276714A 2012-05-22 2014-12-17 Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis CO7160058A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650182P 2012-05-22 2012-05-22
EP12306362 2012-10-31
EP12306472 2012-11-28

Publications (1)

Publication Number Publication Date
CO7160058A2 true CO7160058A2 (es) 2015-01-15

Family

ID=49711434

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14276714A CO7160058A2 (es) 2012-05-22 2014-12-17 Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis

Country Status (15)

Country Link
US (2) US20150150841A1 (enExample)
EP (1) EP2852385B1 (enExample)
CN (1) CN104487068B (enExample)
BR (1) BR112014028706B1 (enExample)
CO (1) CO7160058A2 (enExample)
CR (1) CR20140526A (enExample)
DO (1) DOP2014000257A (enExample)
EA (1) EA201492173A1 (enExample)
IL (1) IL235752A0 (enExample)
IN (1) IN2014KN02584A (enExample)
MX (1) MX368416B (enExample)
PE (1) PE20150022A1 (enExample)
PL (1) PL2852385T3 (enExample)
TN (1) TN2014000484A1 (enExample)
WO (1) WO2013182423A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025606A1 (en) * 2017-08-03 2019-02-07 Bionoox Sa COMPOSITIONS FOR USE IN THE TREATMENT OF SKIN LEHYMANIOSIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
AU2002231175A1 (en) * 2000-12-27 2002-07-08 Focal, Inc. Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Also Published As

Publication number Publication date
PL2852385T3 (pl) 2020-03-31
IL235752A0 (en) 2015-01-29
CR20140526A (es) 2014-12-01
US20160151326A1 (en) 2016-06-02
TN2014000484A1 (en) 2016-03-30
WO2013182423A1 (en) 2013-12-12
BR112014028706B1 (pt) 2023-01-10
BR112014028706A2 (pt) 2017-06-27
MX2014014258A (es) 2016-04-25
US20150150841A1 (en) 2015-06-04
PE20150022A1 (es) 2015-02-09
CN104487068B (zh) 2018-09-11
MX368416B (es) 2019-10-02
EA201492173A1 (ru) 2015-04-30
CN104487068A (zh) 2015-04-01
IN2014KN02584A (enExample) 2015-05-08
US9700540B2 (en) 2017-07-11
EP2852385B1 (en) 2019-08-21
DOP2014000257A (es) 2014-12-15
EP2852385A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
MX2021008901A (es) Compuestos conjugados antisentido y su uso.
BR112016011830A2 (pt) composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
MX2015003140A (es) Formulaciones de enzalutamida.
HUE051105T2 (hu) Sejt életképességének javítására szolgáló készítmények és azok alkalmazására szolgáló eljárások
CO7101248A2 (es) Compuesos de tetrazolinona y su uso como pesticidas
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
BR112013023600A2 (pt) bactérias probióticas tendo atividade antioxidante e uso das mesmas
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112014016243A2 (pt) apoio de braço, em particular para uso em cadeiras de escritório
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
CL2015001689A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112013012175A2 (pt) combinação, coadministração, uso e método
UY34829A (es) Nueva dosificación y formulación
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CL2016000998A1 (es) Composición herbaria, procedimiento para su preparación y uso de la misma
CO7151533A2 (es) Promotores vegetales inducibles y su uso